Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia

Our preliminary results suggest that in individuals with He-FH, a 3-month treatment period with rosuvastatin determines a significant reduction in arterial stiffness, possibly through its pleiotropic vascular effect beyond lowering of plasma cholesterol.